All protocols
Cognitive / Nootropic

Cerebrolysin Peptide Protocol & Dosing

Updated 1mo ago 6 min read 312+ helpful
Validity Score

Validity Score

70 Usable
Evidence 86
Community 70
Completeness 43
Actionability 40
Coverage 80
Penalty -0

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

Cerebrolysin is a porcine-brain-derived peptide mixture studied for stroke recovery, dementia, and traumatic brain injury.

Evidence boundary

Human trial literature exists for stroke, dementia, and traumatic brain injury.

Trial evidence

  • PMID 41880098 — Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
  • PMID 39834702 — Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis.
  • PMID 39534815 — Evaluating the Effectiveness of Neuroprotective Strategies in Enhancing Post-stroke Recovery: A Systematic Review of Meta-Analyses and Clinical Trials.
  • PMID 39256156 — Evidence-Based Review of Randomized Controlled Trials of Interventions for Mental Health Management Post-Moderate to Severe Traumatic Brain Injury.

Preparation and measurement

Cerebrolysin is a ready-to-use liquid. No reconstitution is needed.

Reference schedule

Reference schedule
SettingDoseDraw / measureFrequencyWeekly total
Reference5 mL ready-to-use solutionNo reconstitutionOnce daily IM35 mL/week
Higher-acuity use10 mL ready-to-use solutionNo reconstitutionOnce daily slow IV70 mL/week

Reference

Dose
5 mL ready-to-use solution
Draw / measure
No reconstitution
Frequency
Once daily IM
Weekly total
35 mL/week

Higher-acuity use

Dose
10 mL ready-to-use solution
Draw / measure
No reconstitution
Frequency
Once daily slow IV
Weekly total
70 mL/week

Weekly totals apply only during the active phase.

Titration rules

  • No home titration is established.

  • protocols select the ampoule volume by indication.

  • Do not convert the commercial mixture into an invented mg-peptide dose.

  • Stroke recovery outcomes

  • Dementia symptom response

  • TBI recovery signals

  • Tolerability

  • Injection-site reactions

  • Rare hypersensitivity reactions

  • Headache or blood-pressure effects during IV use

Practical rules

  • Keep IV use in a medical setting.
  • Use the liquid presentation as supplied.
  • Do not frame this as a single-peptide nootropic.
Was this protocol helpful?
Share via

Related protocols

Semax Peptide Protocol & DosingSelank Peptide Protocol & DosingAdamax Peptide Protocol & DosingPE-22-28 Peptide Protocol & Dosing